Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Non Small Cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
Overview
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Primary outcome measures
- Rate of ctDNA Detection [Time frame: Up to 24 Months]
- Relapse Free Survival [Time frame: Up to 36 Months]
Secondary outcome measures (1)
- Overall Survival [Time frame: Up to 36 Months]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years;
- Ability to provide written informed consent;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- T1-T4 (T3,T4 multifocal) N0M0 NSCLC who are planned for complete surgical resection;
- Tumour size must be at least 1 cm (unidimensional) and have at least some solid component on imaging;
- Surgical tumour formalin-fixed, paraffin-embedded (FFPE) specimens for ctDNA studies are required.
Exclusion criteria
- Prior radiation, surgery or chemotherapy for the current diagnosis of NSCLC is not permitted.
- Incomplete surgical resection. Participants who had pre-operative ctDNA samples taken but subsequently do not have a complete surgical resection would not qualify for post-operative ctDNA testing.
- Concurrent enrolment in a therapeutic study using drug or radiation therapy. Enrolment in observational, diagnostic or studies of novel surgical techniques will be allowed.
- Concurrent active malignancy or other invasive malignancy within previous 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition.
- Pregnancy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Canada · 3 centers
- Michael Garron Hospital — Toronto
- St. Joseph's Health Centre — Toronto
- University Health Network — Toronto
Publications
- Feng J, Khan S, Waddell TK, Yasufuku K, Coyne Z, Kelly D, Meti N, Safieddine N, Ko M, Pierre A, Keshavjee S, Wakeam E, Donahoe L, Cypel M, Yeung J, de Perrot M, Ahmadi N, Gazala S, Simone C, Parente D, Rabey MR, Law JH, Li JJN, Salvarrey A, Le LW, Seto A, Cabanero M, Tsao MS, Pipinikas C, Chevalier A, Bratman SV, Leighl NB. Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed P PMID 41730473
Identifiers
NCT: NCT05254782 · 20-6199